Higher than expected sales of specialty and improving traction in Ilumya were key positives; ‘Buy’ maintained with target price of Rs 525
from The Financial Express https://ift.tt/2AnzWef
Sunday, 31 May 2020
Sun Pharma rating: Buy — Quarter results were in line with estimates
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment